High IDL causes

	Intermediate Density Lipoprotein Microchapters
Home
Patient information
Overview
Historical Perspective
Classification
Biochemistry
Physiology
Clinical Correlation
High IDL Epidemiology and Demographics Pathophysiology Causes Diseases Prognosis and Complications
Low IDL Epidemiology and Demographics Pathophysiology Causes Diseases Prognosis and Complications
Treatment
Medical Therapy
Primary Prevention
Secondary Prevention
Landmark Trials
Future or Investigational Therapies
Case Studies
Case #1
High IDL causes On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of High IDL causes All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on High IDL causes
CDC on High IDL causes
High IDL causes in the news
Blogs on High IDL causes
Directions to Hospitals Treating Intermediate density lipoprotein
Risk calculators and risk factors for High IDL causes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ogheneochuko Ajari, MB.BS, MS [2]

Overview

Disorders that would increase or cause high IDL may be due to defects or deficiency in the lipoprotein particle, endocrine causes, familial and metabolic causes.

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.

There are no life threatening causes of high IDL.

Common Causes

Causes by Organ System

Cardiovascular	Hypocalcemia, Reaven X syndrome
Chemical/Poisoning	No underlying causes
Dental	No underlying causes
Dermatologic	No underlying causes
Drug Side Effect	No underlying causes
Ear Nose Throat	No underlying causes
Endocrine	Diabetes mellitus type 2, diabetic nephropathy, hyperparathyroidism, hypocalcemia, Reaven X syndrome
Environmental	No underlying causes
Gastroenterologic	Glycogen storage disease type 1a
Genetic	Apolipoprotein E deficiency, decreased hepatic triglyceride lipase, familial alphalipoprotein deficiency, glycogen storage disease type 1a, Reaven X syndrome
Hematologic	No underlying causes
Iatrogenic	No underlying causes
Infectious Disease	No underlying causes
Musculoskeletal/Orthopedic	No underlying causes
Neurologic	No underlying causes
Nutritional/Metabolic	Glycogen storage disease type 1a, hypocalcemia, Reaven X syndrome
Obstetric/Gynecologic	No underlying causes
Oncologic	No underlying causes
Ophthalmologic	Diabetes mellitus type 2
Overdose/Toxicity	No underlying causes
Psychiatric	No underlying causes
Pulmonary	No underlying causes
Renal/Electrolyte	Chronic renal failure, diabetes mellitus type 2, diabetic nephropathy, hypocalcemia
Rheumatology/Immunology/Allergy	Reaven syndrome X
Sexual	No underlying causes
Trauma	No underlying causes
Urologic	No underlying causes
Miscellaneous	No underlying causes

Causes in Alphabetical Order

References

↑ Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H (1999). "Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients". Kidney Int Suppl. 71: S134–6. PMID 10412757.
↑ ^2.0 ^2.1 ^2.2 Nishizawa Y, Shoji T, Kawagishi T, Morii H (1997). "Atherosclerosis in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation". Kidney Int Suppl. 62: S90–2. PMID 9350691.
↑ Oi K, Hirano T, Sakai S, Kawaguchi Y, Hosoya T (1999). "Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients". Kidney Int Suppl. 71: S227–8. PMID 10412783.
↑ Durrington PN (1993). "Diabetes, hypertension and hyperlipidaemia". Postgrad Med J. 69 Suppl 1: S18–25, discussion S25-9. PMID 8497453.
↑ Shoji T, Emoto M, Kawagishi T, Kimoto E, Yamada A, Tabata T; et al. (2001). "Atherogenic lipoprotein changes in diabetic nephropathy". Atherosclerosis. 156 (2): 425–33. PMID 11395040.
↑ Geberhiwot T, Alger S, McKiernan P, Packard C, Caslake M, Elias E; et al. (2007). "Serum lipid and lipoprotein profile of patients with glycogen storage disease types I, III and IX". J Inherit Metab Dis. 30 (3): 406. doi:10.1007/s10545-007-0485-2. PMID 17407002.
↑ Levy E, Thibault LA, Roy CC, Bendayan M, Lepage G, Letarte J (1988). "Circulating lipids and lipoproteins in glycogen storage disease type I with nocturnal intragastric feeding". J Lipid Res. 29 (2): 215–26. PMID 3130454.

Template:WH Template:WS

[pmid10412757-1] Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H (1999). "Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients". Kidney Int Suppl. 71: S134–6. PMID 10412757.

[pmid9350691-2] 2.0 ^2.1 ^2.2 Nishizawa Y, Shoji T, Kawagishi T, Morii H (1997). "Atherosclerosis in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation". Kidney Int Suppl. 62: S90–2. PMID 9350691.

[pmid10412783-3] Oi K, Hirano T, Sakai S, Kawaguchi Y, Hosoya T (1999). "Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients". Kidney Int Suppl. 71: S227–8. PMID 10412783.

[pmid8497453-4] Durrington PN (1993). "Diabetes, hypertension and hyperlipidaemia". Postgrad Med J. 69 Suppl 1: S18–25, discussion S25-9. PMID 8497453.

[pmid11395040-5] Shoji T, Emoto M, Kawagishi T, Kimoto E, Yamada A, Tabata T; et al. (2001). "Atherogenic lipoprotein changes in diabetic nephropathy". Atherosclerosis. 156 (2): 425–33. PMID 11395040.

[pmid17407002-6] Geberhiwot T, Alger S, McKiernan P, Packard C, Caslake M, Elias E; et al. (2007). "Serum lipid and lipoprotein profile of patients with glycogen storage disease types I, III and IX". J Inherit Metab Dis. 30 (3): 406. doi:10.1007/s10545-007-0485-2. PMID 17407002.

[pmid3130454-7] Levy E, Thibault LA, Roy CC, Bendayan M, Lepage G, Letarte J (1988). "Circulating lipids and lipoproteins in glycogen storage disease type I with nocturnal intragastric feeding". J Lipid Res. 29 (2): 215–26. PMID 3130454.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

v t e Lipopedia
Basic Science	Cholesterol • Triglyceride Lipoprotein metabolism and transport Lipoprotein: Chylomicron • Chylomicron remnant • HDL • IDL • LDL • Lipoprotein(a) • VLDL • Lipoprotein-X Apolipoprotein: APOA (1, 2, 4, 5) • APOB ( Apolipoprotein B-48, Apolipoprotein B-100) • APOC (1, 2, 3, 4) • APOD • APOE • APOH • APOJ • APOL • APOM • Apo(a) Lipoprotein receptor: LDL receptor • Soluble low density lipoprotein receptor-related protein (sLRP) • Apolipoprotein E Receptor 2 • Scavenger receptor • Scavenger receptor A • Scavenger receptor B • VLDL receptor Lipoprotein enzymes: Lipoprotein lipase • Lipoprotein-associated phospholipase A2 (Lp-PLA2) • Cholesterylester transfer protein ( Acetyl-CoA C-acyltransferase, Lecithin-cholesterol acyltransferase) • Microsomal triglyceride transfer protein • ABCA1 Genes: Low density lipoprotein receptor gene family • Microsomal triglyceride transfer protein • ABCA1
Lipoprotein Disorders	Lipoprotein disorders Primary lipoprotein disorders: Familial hyperchylomicronemia (Type I) • Familial hypercholesterolemia (Type IIA) • Familial combined hyperlipidemia (Type IIB) • Dysbetalipoproteinemia (Type III) • Primary hypertriglyceridemia (Type IV) • Mixed hyperlipoproteinemia (Type V) Secondary lipoprotein disorders
Abnormal Laboratory Lipid Profile	Low chylomicron • Low chylomicron remnant • Low HDL • Low IDL • Low LDL • Low lipoprotein(a) • Low VLDL High chylomicron • High chylomicron remnant • High HDL • High IDL • High LDL • High Lipoprotein(a) • High VLDL